https://orcid.org/0000-0002-1456-6887
Key Points
This study provides an overall picture of driver mutations in ML-DS, including novel and frequent IRX1 and ZBTB7A mutations, and RUNX1-PTD.
CDKN2A and TP53 deletions and/or mutations are associated with a poor prognosis in ML-DS.
Abstract
Transient abnormal myelopoiesis (TAM) is a common complication in newborns with Down syndrome (DS). It commonly progresses to myeloid leukemia (ML-DS) after spontaneous regression. In contrast to the favorable prognosis of primary ML-DS, patients with refractory/relapsed ML-DS have poor outcomes. However, the molecular basis for refractoriness and relapse and the full spectrum of driver mutations in ML-DS remain largely unknown. We conducted a genomic profiling study of 143 TAM, 204 ML-DS, and 34 non-DS acute megakaryoblastic leukemia cases, including 39 ML-DS cases analyzed by exome sequencing. Sixteen novel mutational targets were identified in ML-DS samples. Of these, inactivations of IRX1 (16.2%) and ZBTB7A (13.2%) were commonly implicated in the upregulation of the MYC pathway and were potential targets for ML-DS treatment with bromodomain-containing protein 4 inhibitors. Partial tandem duplications of RUNX1 on chromosome 21 were also found, specifically in ML-DS samples (13.7%), presenting its essential role in DS leukemia progression. Finally, in 177 patients with ML-DS treated following the same ML-DS protocol (the Japanese Pediatric Leukemia and Lymphoma Study Group acute myeloid leukemia -D05/D11), CDKN2A, TP53, ZBTB7A, and JAK2 alterations were associated with a poor prognosis. Patients with CDKN2A deletions (n = 7) or TP53 mutations (n = 4) had substantially lower 3-year event-free survival (28.6% vs 90.5%; P < .001; 25.0% vs 89.5%; P < .001) than those without these mutations. These findings considerably change the mutational landscape of ML-DS, provide new insights into the mechanisms of progression from TAM to ML-DS, and help identify new therapeutic targets and strategies for ML-DS.
References
1.
Ito
E
, Kasai
M
, Hayashi
Y
, et al. Expression of erythroid-specific genes in acute megakaryoblastic leukemia and transient myeloproliferative disorder in Down syndrome
. Br J Haematol
. 1995
;90
(3
):607
-614
.2.
Hasle
H
, Niemeyer
CM
, Chessells
JM
, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases
. Leukemia
. 2003
;17
(2
):277
-282
.3.
Wechsler
J
, Greene
M
, McDevitt
MA
, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
. Nat Genet
. 2002
;32
(1
):148
-152
.4.
Mundschau
G
, Gurbuxani
S
, Gamis
AS
, Greene
ME
, Arceci
RJ
, Crispino
JD
. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis
. Blood
. 2003
;101
(11
):4298
-4300
.5.
Hitzler
JK
, Cheung
J
, Li
Y
, Scherer
SW
, Zipursky
A
. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome
. Blood
. 2003
;101
(11
):4301
-4304
.6.
Rainis
L
, Bercovich
D
, Strehl
S
, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21
. Blood
. 2003
;102
(3
):981
-986
.7.
Xu
G
, Nagano
M
, Kanezaki
R
, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome
. Blood
. 2003
;102
(8
):2960
-2968
.8.
Yoshida
K
, Toki
T
, Okuno
Y
, et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders
. Nat Genet
. 2013
;45
(11
):1293
-1299
.9.
Labuhn
M
, Perkins
K
, Matzk
S
, et al. Mechanisms of progression of myeloid preleukemia to transformed myeloid leukemia in children with Down syndrome
. Cancer Cell
. 2019
;36
(3
):340
. 138.10.
Taga
T
, Saito
AM
, Kudo
K
, et al. Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome
. Blood
. 2012
;120
(9
):1810
-1815
.11.
Taub
JW
, Berman
JN
, Hitzler
JK
, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial
. Blood
. 2017
;129
(25
):3304
-3313
.12.
Raghuram
N
, Hasegawa
D
, Nakashima
K
, et al. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
. Blood Adv
. 2023
;7
(21
):6532
-6539
.13.
Taga
T
, Tanaka
S
, Hasegawa
D
, et al. Post-induction MRD by FCM and GATA1-PCR are significant prognostic factors for myeloid leukemia of Down syndrome
. Leukemia
. 2021
;35
(9
):2508
-2516
.14.
Taga
T
, Watanabe
T
, Tomizawa
D
, et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in Down syndrome: a nationwide prospective study in Japan
. Pediatr Blood Cancer
. 2016
;63
(2
):248
-254
.15.
Tomizawa
D
, Tawa
A
, Watanabe
T
, et al. Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group
. Int J Hematol
. 2013
;98
(5
):578
-588
.16.
Yamato
G
, Deguchi
T
, Terui
K
, et al. Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome
. Leukemia
. 2021
;35
(5
):1480
-1484
.17.
Shiraishi
Y
, Tremmel
G
, Miyano
S
, Stephens
M
. A simple model-based approach to inferring and visualizing cancer mutation signatures
. PLoS Genet
. 2015
;11
(12
):e1005657
.18.
Martincorena
I
, Raine
KM
, Gerstung
M
, et al. Universal patterns of selection in cancer and somatic tissues
. Cell
. 2017
;171
(5
):1029
-1041.e21
.19.
Yoshizato
T
, Nannya
Y
, Atsuta
Y
, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
. Blood
. 2017
;129
(17
):2347
-2358
.20.
de Rooij
JD
, Branstetter
C
, Ma
J
, et al. Pediatric non-Down syndrome acute megakaryoblastic leukemia is characterized by distinct genomic subsets with varying outcomes
. Nat Genet
. 2017
;49
(3
):451
-456
.21.
Houweling
AC
, Dildrop
R
, Peters
T
, et al. Gene and cluster-specific expression of the Iroquois family members during mouse development
. Mech Dev
. 2001
;107
(1-2
):169
-174
.22.
Maeda
T
, Ito
K
, Merghoub
T
, et al. LRF is an essential downstream target of GATA1 in erythroid development and regulates BIM-dependent apoptosis
. Dev Cell
. 2009
;17
(4
):527
-540
.23.
Hartmann
L
, Dutta
S
, Opatz
S
, et al. ZBTB7A mutations in acute myeloid leukaemia with t(8;21) translocation
. Nat Commun
. 2016
;7
:11733
.24.
Miyoshi
H
, Ohira
M
, Shimizu
K
, et al. Alternative spicing and genetic structure of the AML1 gene involved in acute myeloid leukemia
. Nucleic Acids Res
. 1995
;23
(14
):2762
-2769
.25.
Klusmann
JH
, Godinho
FJ
, Heitmann
K
, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis
. Genes Dev
. 2010
;24
(15
):1659
-1672
.26.
Pessler
F
, Hernandez
N
. Flexible DNA binding of the BTB/POZ-domain protein FBI-1
. J Biol Chem
. 2003
;278
(31
):29327
-29335
.27.
Delmore
JE
, Issa
GC
, Lemieux
ME
, et al. BET bromodomain inhibition as a therapeutic strategy to target c-MYC
. Cell
. 2011
;146
(6
):904
-917
.28.
Piya
S
, Mu
H
, Bhattacharya
S
, et al. BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment
. J Clin Invest
. 2019
;129
(5
):1878
-1894
.29.
Mateyak
MK
, Obaya
AJ
, Sedivy
JM
. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points
. Mol Cell Biol
. 1999
;19
(7
):4672
-4683
.30.
Xu
G
, Kanezaki
R
, Toki
T
, et al. Physical association of the patient-specific GATA1 mutants with RUNX1 in acute megakaryoblastic leukemia accompanying Down syndrome
. Leukemia
. 2006
;20
(6
):1002
-1008
.31.
Brady
G
, Elgueta Karstegl
C
, Farrell
PJ
. Novel function of the unique N-terminal region of RUNX1c in B cell growth regulation
. Nucleic Acids Res
. 2013
;41
(3
):1555
-1568
.32.
Gronostajski
RM
. Roles of the NFI/CTF gene family in transcription and development
. Gene
. 2000
;249
(1-2
):31
-45
.33.
Starnes
LM
, Sorrentino
A
, Pelosi
E
, et al. NFI-A directs the fate of hematopoietic progenitors to the erythroid or granulocytic lineage and controls beta-globin and G-CSF receptor expression
. Blood
. 2009
;114
(9
):1753
-1763
.34.
Micci
F
, Thorsen
J
, Panagopoulos
I
, et al. High-throughput sequencing identifies an NFIA/CBFA2T3 fusion gene in acute erythroid leukemia with t(1;16)(p31;q24)
. Leukemia
. 2013
;27
(4
):980
-982
.35.
Yoshihara
K
, Wang
Q
, Torres-Garcia
W
, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions
. Oncogene
. 2015
;34
(37
):4845
-4854
.36.
Hakimi
MA
, Dong
Y
, Lane
WS
, Speicher
DW
, Shiekhattar
R
. Candidate X-linked mental retardation gene is a component of a new family of histone deacetylase-containing complexes
. J Biol Chem
. 2003
;278
(9
):7234
-7239
.37.
Wang
ET
, Cody
NA
, Jog
S
, et al. Transcriptome-wide regulation of pre-mRNA splicing and mRNA localization by muscleblind proteins
. Cell
. 2012
;150
(4
):710
-724
.38.
Cheng
AW
, Shi
J
, Wong
P
, et al. Muscleblind like 1 (Mbnl1) regulates pre-mRNA alternative splicing during terminal erythropoiesis
. Blood
. 2014
;124
(4
):598
-610
.39.
Bolouri
H
, Farrar
JE
, Triche
T
, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions
. Nat Med
. 2018
;24
(1
):103
-112
.40.
Matsuyama
T
, Kimura
T
, Kitagawa
M
, et al. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development
. Cell
. 1993
;75
(1
):83
-97
.41.
Xu
J
, Shao
Z
, Glass
K
, et al. Combinatorial assembly of developmental stage-specific enhancers controls gene expression programs during human erythropoiesis
. Dev Cell
. 2012
;23
(4
):796
-811
.42.
Jutzi
JS
, Bogeska
R
, Nikoloski
G
, et al. MPN patients harbor recurrent truncating mutations in transcription factor NF-E2
. J Exp Med
. 2013
;210
(5
):1003
-1019
.43.
Jutzi
JS
, Basu
T
, Pellmann
M
, et al. Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations
. Blood
. 2019
;133
(16
):1766
-1777
.44.
Iacobucci
I
, Li
Y
, Roberts
KG
, et al. Truncating erythropoietin receptor rearrangements in acute lymphoblastic leukemia
. Cancer Cell
. 2016
;29
(2
):186
-200
.45.
Takeda
J
, Yoshida
K
, Nakagawa
MM
, et al. Amplified EPOR/JAK2 genes define a unique subtype of acute erythroid leukemia
. Blood Cancer Discov
. 2022
;3
(5
):410
-427
.46.
de la Chapelle
A
, Träskelin
AL
, Juvonen
E
. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis
. Proc Natl Acad Sci U S A
. 1993
;90
(10
):4495
-4499
.47.
Burkhart
DL
, Sage
J
. Cellular mechanisms of tumour suppression by the retinoblastoma gene
. Nat Rev Cancer
. 2008
;8
(9
):671
-682
.48.
González-Gil
C
, Ribera
J
, Ribera
JM
, Genescà
E
. The Yin and Yang-Like clinical implications of the CDKN2A/ARF/CDKN2B gene cluster in acute lymphoblastic leukemia
. Genes
. 2021
;12
(1
):79
.49.
Faderl
S
, Kantarjian
HM
, Estey
E
, et al. The prognostic significance of p16(INK4a)/p14(ARF) locus deletion and MDM-2 protein expression in adult acute myelogenous leukemia
. Cancer
. 2000
;89
(9
):1976
-1982
.50.
Papaemmanuil
E
, Gerstung
M
, Bullinger
L
, et al. Genomic classification and prognosis in acute myeloid leukemia
. N Engl J Med
. 2016
;374
(23
):2209
-2221
.51.
Mullighan
CG
, Zhang
J
, Harvey
RC
, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia
. Proc Natl Acad Sci U S A
. 2009
;106
(23
):9414
-9418
.52.
Roberts
KG
, Li
Y
, Payne-Turner
D
, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia
. N Engl J Med
. 2014
;371
(11
):1005
-1015
.53.
Brady
SW
, Roberts
KG
, Gu
Z
, et al. The genomic landscape of pediatric acute lymphoblastic leukemia
. Nat Genet
. 2022
;54
(9
):1376
-1389
.54.
Li
Z
, Chang
TC
, Junco
JJ
, et al. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia
. Blood
. 2023
;142
(2
):172
-184
.55.
Klusmann
JH
, Creutzig
U
, Zimmermann
M
, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
. Blood
. 2008
;111
(6
):2991
-2998
.56.
Gamis
AS
, Alonzo
TA
, Gerbing
RB
, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971
. Blood
. 2011
;118
(26
):6752
-6996
.57.
Ichikawa
M
, Yoshimi
A
, Nakagawa
M
, Nishimoto
N
, Watanabe-Okochi
N
, Kurokawa
M
. A role for RUNX1 in hematopoiesis and myeloid leukemia
. Int J Hematol
. 2013
;97
(6
):726
-734
.58.
Korbel
JO
, Tirosh-Wagner
T
, Urban
AE
, et al. The genetic architecture of Down syndrome phenotypes revealed by high-resolution analysis of human segmental trisomies
. Proc Natl Acad Sci U S A
. 2009
;106
(29
):12031
-12036
.59.
Banno
K
, Omori
S
, Hirata
K
, et al. Systematic cellular disease models reveal synergistic interaction of trisomy 21 and GATA1 mutations in hematopoietic abnormalities
. Cell Rep
. 2016
;15
(6
):1228
-1241
.60.
Gialesaki
S
, Bräuer-Hartmann
D
, Issa
H
, et al. RUNX1 isoform disequilibrium promotes the development of trisomy 21-associated myeloid leukemia
. Blood
. 2023
;141
(10
):1105
-1118
.© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.
2024
You do not currently have access to this content.
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal